Experts are increasingly investigating retatrutide, a novel medication developed by Eli Lilly, as a possible breakthrough in physique management. Unlike many previous approaches, retatrutide is a double -action agonist targeting simultaneously GLP-1 and GIP, hormones that impact satiety and bloo